DUBLIN--(BUSINESS WIRE)--The "Gastroparesis Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2026" report has been added to ResearchAndMarkets.com's offering.
In gastroparesis Dopamine (D2) receptor is a major focus of drug developers. There are 17 drugs in the pipeline with 90% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication.
The rising prevalence and more frequent use of newer symptomatic treatments are expected to drive the market. However, the market growth is limited by delayed diagnosis, frequent usage of over-the-counter medicines, and decreased compliance due to side effects associated with gastroparesis therapies.
This reports provides a data-driven overview of the current and future competitive landscape in gastroparesis therapeutics.
Components of the report include:
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the gastroparesis market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global gastroparesis market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Key Topics Covered:
1 Preface
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
4.2 Marketed Drug Profiles
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.3 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
8.1 Key Twitter Chatter
8.2 Top Branded Websites
8.3 Trust Flow and Citation Flow
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/o1vwp9
